Express Pharma

Laurus Labs finishes USFDA inspection of its API facilities in Visakhapatnam

15

“This was a regular surveillance audit by US FDA, and no data integrity issues were observed in the inspection,” the company stated

Laurus Labs announced that it has completed the US Food and Drug Administration (US FDA) inspection of its API facilities in Units 1 & 3 at Parawada, Visakhapatnam, Andhra Pradesh, with two observations which are procedural in nature.

“This was a regular surveillance audit by US FDA, and no data integrity issues were observed in the inspection,” the company stated in a press release.

Comments are closed.